Published on : Dec 22, 2016
ALBANY, NY, Dec 22, 2016: The research publication is an evaluation of the historic and present growth trajectory along with the future growth prospects of the global next-generation biologics market. The important elements at play and the predominant trends have also been highlighted in the report. The report also offers an overview of the factors that are expected to influence the growth of the global next-generation biologics market. The share, products, and strategies of the prime companies have also been mentioned in the study.
According to the report, the global next-generation biologics market is anticipated to witness a significant 14.42% CAGR between 2016 and 2020. The growth of the market can be attributed to the rising demand for antibody drug conjugates across the globe. Antibody drug conjugates are highly operative cytotoxic drugs linked to mAbs. These drugs are efficient and potent in treating diseases such as hematological malignancies and cancers. As a result of this, antibodies have gained preferences among consumers to treat inflammatory diseases, oncology, and respiratory diseases. The employment of antibody drug conjugates in the form of antibody directed enzyme prodrug and radio-immunotherapy is rising extensively. The growing use of these products is expected to bode well for the growth of the global next-generation biologics market.
Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=892950
The trend that has been recently gaining traction in the market is the introduction of combination and targeted therapies for treating several diseases such as cancer and viral infections. This trend is gaining importance basically due to the fact that targeted therapies have fewer side effects as compared to the traditional non-targeted therapies. On the basis of therapies, the global next-generation biologics market has been classified into next-generation insulin products, next-generation antibodies market, next-generation recombinant coagulation factors, and next-generation regenerative medicine. Among these four, next-generation regenerative medicine emerged dominant in the market and is likely to retain a lead in the near future.
The progress of this segment can be attributed to the rising need for stem cell and tissue-engineered products for various treatment purposes. Other factors driving the growth of the market are a rise in government funding towards research and development projects, growing cases of chronic diseases, and rising focus of companies on cell therapy products. Region-wise, the global next-generation biologics market has been classified into Europe, the Middle East and Africa, Asia Pacific, and the Americas. The Americas led the market in the past and are likely to retain its dominance owing to the surging approvals for different advanced formulations. The leading companies in the global next-generation biologics market are Takeda Pharmaceuticals, Sanofi, Novo Nordisk, and F. Hofmann-La Roche.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org